Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. 1998

J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
Department of Surgery, Kuopio University Hospital, Finland.

Clinical data from 369 patients with clinical stage I cutaneous malignant melanoma treated in Kuopio University Hospital district between 1974 and 1989 with a mean follow-up of 6.4 years were analysed. Clinical parameters, histology, DNA index, S-phase fraction (SPF) and mitotic indices [mitotic activity index (MAI) and volume-corrected mitotic index (M/V index)] were correlated with the outcome of the disease to establish their value as predictors of stage I cutaneous malignant melanoma. In univariate survival analyses, bleeding, gender, tumour thickness, level of invasion according to Clark, TNM category, MAI, M/V index and SPF were the most significant predictors of recurrence-free (RFS) and overall survival. In Cox's multivariate analysis, tumour thickness (P = 0.0021), bleeding (P = 0.0106) and M/V index (P = 0.0058) predicted poor RFS in the 259 patients available for the analysis. Poor overall survival was predicted by MAI (P = 0.0002), bleeding (P = 0.004), SPF (P = 0.009) and male gender (P = 0.034). The present results indicate that mitotic activity index (MAI), volume-corrected mitotic index (M/V index) and S-phase fraction (SPF) are important prognostic factors in addition to the well-established Breslow thickness in stage I cutaneous malignant melanoma.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008938 Mitosis A type of CELL NUCLEUS division by means of which the two daughter nuclei normally receive identical complements of the number of CHROMOSOMES of the somatic cells of the species. M Phase, Mitotic,Mitotic M Phase,M Phases, Mitotic,Mitoses,Mitotic M Phases,Phase, Mitotic M,Phases, Mitotic M
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
February 2000, Canadian journal of surgery. Journal canadien de chirurgie,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
October 2019, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
January 1993, British journal of cancer,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
June 1983, Cancer research,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
January 1978, Scandinavian journal of plastic and reconstructive surgery,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
September 1984, Analytical and quantitative cytology,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
September 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
May 1990, The Journal of dermatologic surgery and oncology,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
May 1994, Cancer,
J M Karjalainen, and M J Eskelinen, and S Nordling, and P K Lipponen, and E M Alhava, and V M Kosma
December 2002, Pathologica,
Copied contents to your clipboard!